Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00092573
First received: September 23, 2004
Last updated: May 24, 2013
Last verified: May 2013

September 23, 2004
May 24, 2013
January 2003
November 2004   (final data collection date for primary outcome measure)
Tolerability
Not Provided
Complete list of historical versions of study NCT00092573 on ClinicalTrials.gov Archive Site
Plasma LDL-C, HDL-C and triglycerides after 12 weeks.
Not Provided
Not Provided
Not Provided
 
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia

The purpose of this study is to assess the cholesterol lowering safety and effectiveness of two investigational drugs in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).

The duration of treatment is 48 weeks.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Primary Purpose: Treatment
  • Hypercholesterolemia
  • Hypertriglyceridemia
  • Drug: MK0653, ezetimibe
  • Drug: Comparator: fenofibrate monotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
Not Provided
November 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • High cholesterol and high triglycerides

Exclusion Criteria:

  • Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00092573
2004_036, MK0653-036
Not Provided
Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP